Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation

Breast Cancer Research and Treatment

Volumn 128, Issue 3, 2011, Pages 899-906

  Panoff, J E ^a   Hurley, J ^a   Takita, C ^a   Reis, I M ^a,b   Zhao, W ^b   Sujoy, V ^a   Gomez, C R ^a   Jorda, M ^a   Koniaris, L ^a   Wright, J L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PLATINUM; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; DRUG TARGETING; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK; TREATMENT OUTCOME;

EID: 79960845909     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1495-1     Document Type: Article

References (21)

1. WA Woodward PT Truong TK Yu W Tereffe J Oh G Perkins E Strom F Meric-Bernstam AM Gonzalez-Angulo C Speers, et al. 2010 Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival Breast Cancer Res Treat 123 2 597 605 20306128 10.1007/s10549-010-0829-8
2. M Overgaard PS Hansen J Overgaard C Rose M Andersson F Bach M Kjaer CC Gadeberg HT Mouridsen MB Jensen, et al. 1997 Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial N Engl J Med 337 14 949 955 9395428 10.1056/NEJM199710023371401 1:STN:280:DyaK2svktFSitA%3D%3D (Pubitemid 27425950)
3. M Overgaard MB Jensen J Overgaard PS Hansen C Rose M Andersson C Kamby M Kjaer CC Gadeberg BB Rasmussen, et al. 1999 Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial Lancet 353 9165 1641 1648 10335782 10.1016/S0140-6736(98)09201-0 1:CAS:528:DyaK1MXjsleksLk%3D (Pubitemid 29224519)
4. J Ragaz IA Olivotto JJ Spinelli N Phillips SM Jackson KS Wilson MA Knowling CM Coppin L Weir K Gelmon, et al. 2005 Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial J Natl Cancer Inst 97 2 116 126 15657341 10.1093/jnci/djh297 (Pubitemid 40277091)
5. M Clarke R Collins S Darby C Davies P Elphinstone E Evans J Godwin R Gray C Hicks S James, et al. 2005 Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 9503 2087 2106 16360786 1:STN:280:DC%2BD2MnnsVSitA%3D%3D (Pubitemid 41797643)
6. M Kyndi FB Sorensen H Knudsen M Overgaard HM Nielsen J Overgaard 2008 Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group J Clin Oncol 26 9 1419 1426 18285604 10.1200/JCO.2007.14.5565 1:CAS:528:DC%2BD1cXkslKqs7c%3D
7. KD Voduc MC Cheang S Tyldesley K Gelmon TO Nielsen H Kennecke 2010 Breast cancer subtypes and the risk of local and regional relapse J Clin Oncol 28 10 1684 1691 20194857 10.1200/JCO.2009.24.9284
8. J Hurley P Doliny I Reis O Silva C Gomez-Fernandez P Velez G Pauletti JE Powell MD Pegram DJ Slamon 2006 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 12 1831 1838 16549824 10.1200/JCO.2005.02.8886 1:CAS:528:DC%2BD28XkvVajt7k%3D (Pubitemid 46638980)
9. R Gray 1988 A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1141 1154 10.1214/aos/1176350951
10. The R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Version 2.8.0 (2008-10-20), ISBN 3-900051-07-0. http://cran.r-project.org/doc/manuals/refman. pdf
11. JPGR Fine 1999 A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 496 509 10.2307/2670170
12. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka LA Lickley E Rawlinson P Sun SA Narod 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 15 Pt 1 4429 4434 17671126 10.1158/1078-0432.CCR-06-3045 (Pubitemid 47219710)
13. GM Freedman PR Anderson T Li N Nicolaou 2009 Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation Cancer 115 5 946 951 19156929 10.1002/cncr.24094
14. BG Haffty Q Yang M Reiss T Kearney SA Higgins J Weidhaas L Harris W Hait D Toppmeyer 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 36 5652 5657 17116942 10.1200/JCO.2006.06.5664 (Pubitemid 46631305)
15. PL Nguyen AG Taghian MS Katz A Niemierko RF Abi Raad WL Boon JR Bellon JS Wong BL Smith JR Harris 2008 Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 14 2373 2378 18413639 10.1200/JCO.2007.14.4287
16. EK Millar PH Graham SA O'Toole CM McNeil L Browne AL Morey S Eggleton J Beretov C Theocharous A Capp 2009 Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel J Clin Oncol 27 28 4701 4708 19720911 10.1200/JCO.2008.21.7075
17. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
18. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga, et al. 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 9555 29 36 17208639 10.1016/S0140- 6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D (Pubitemid 46039831)
19. S Chumsri S Jeter LK Jacobs H Nassar DK Armstrong LA Emens JH Fetting JR Lange C Riley TN Tsangaris, et al. 2010 Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer Clin Breast Cancer 10 1 40 45 20133257 10.3816/CBC.2010.n.005 1:CAS:528: DC%2BC3cXisFeqsLc%3D
20. F Peintinger AU Buzdar HM Kuerer JA Mejia C Hatzis AM Gonzalez-Angulo L Pusztai FJ Esteva SS Dawood MC Green, et al. 2008 Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab Ann Oncol 19 12 2020 2025 18667396 10.1093/annonc/mdn427 1:STN:280:DC%2BD1cjlsFChtw%3D%3D
21. M Kyndi M Overgaard HM Nielsen FB Sorensen H Knudsen J Overgaard 2009 High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c Radiother Oncol 90 1 74 79 18471914 10.1016/j.radonc.2008.04.014